Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5591 - Comparison of preoperative neoadjuvant chemotherapy(SOX) with different courses of treatment on the patients with advanced gastric cancer

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Cytotoxic Therapy

Tumour Site

Gastric Cancer

Presenters

Xinxin Wang

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

X. Wang

Author affiliations

  • General Surgery, Chinese PLA General Hospital, 100853 - Beijing/CN

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5591

Background

Objective: To analyze the safety and efficacy of different periods of preoperative adjuvant chemotherapy (SOX) regimen in the treatment of advanced gastric cancer.

Methods

From June 1 2010 to June 1 2017, 120 patients aged from 25 to 80 with clinical stage IIA-IIIC gastric cancer received neoadjuvant chemotherapy with S-1 and oxaliplatin and gastrectomy in Chinese PLA General Hospital. Patients were randomly assigned to two groups with different length of treatment in preoperative neoadjuvant chemotherapy. There were 60 patients in the group with 3 periods preoperative neoadjuvant chemotherapy of treatment, and 60 patients in the group with 5 periods preoperative neoadjuvant chemotherapy of treatment. An ambispective cohort study was conducted. We compared short-term surgical outcomes between the two groups.

Results

There was no significant difference in clinical pathological features between the two groups. However, the five-cycle group had less operative time (229 minutes vs 240 minutes, P = 0.031) and less intraoperative blood loss (158 ml vs. 201 ml, P = 0.006). The short-term prognosis was similar in both groups. The R0 resection rate was higher in the 5-cycle group, especially in stage III subgroup.

Conclusions

The longer preoperative chemotherapy in neoadjuvant chemotherapy, the better the effect of the neoadjuvant chemotherapy in patients with advanced gastric cancer, so we can try to use more preoperative neoadjuvant chemotherapy.

Clinical trial identification

Legal entity responsible for the study

Chinese PLA general hospital.

Funding

Chinese national nature science foundation and Beijing\'s NOVO programme.

Editorial Acknowledgement

Disclosure

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.